Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
News|Articles|August 19, 2026
What Nurses Need to Know About FDA-Approved Iberdomide in Multiple Myeloma
Author(s)By ONN Staff
Fact checked by: Alex Biese
Oncology clinical trial nurse navigator Elise Curry, RN, breaks down the key clinical questions surrounding the FDA approval of oral iberdomide.
Advertisement
Advertisement
The FDA granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) combined with daratumumab and hyaluronidase-fihj and dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. This approval introduces the first approved cereblon E3 ligase modulator (CELMoD) agent, establishing a novel therapeutic class in the myeloma landscape.
Related to this article
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.
An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
Advertisement
Advertisement